HROW Quote, Financials, Valuation and Earnings

FibroGen, Inc. has a net margin of 1.42% compared to Harrow, Inc.'s net margin of -1221.75%. Harrow, Inc.'s return on equity of -8.95% beat FibroGen, Inc.'s return on equity of --.

Harrow, Inc. has a consensus price target of $70.63, signalling upside risk potential of 43.69%. On the other hand FibroGen, Inc. has an analysts' consensus of $43.00 which suggests that it could grow by 410.08%. Given that FibroGen, Inc. has higher upside potential than Harrow, Inc., analysts believe FibroGen, Inc. is more attractive than Harrow, Inc..

Harrow, Inc. has a beta of 0.068, which suggesting that the stock is 93.168% less volatile than S&P 500. In comparison FibroGen, Inc. has a beta of 0.747, suggesting its less volatile than the S&P 500 by 25.347%.

Harrow, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FibroGen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harrow, Inc. pays -- of its earnings as a dividend. FibroGen, Inc. pays out -- of its earnings as a dividend.

Harrow, Inc. quarterly revenues are $71.6M, which are larger than FibroGen, Inc. quarterly revenues of $1.1M. Harrow, Inc.'s net income of $1M is higher than FibroGen, Inc.'s net income of -$13.1M. Notably, Harrow, Inc.'s price-to-earnings ratio is -- while FibroGen, Inc.'s PE ratio is 0.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow, Inc. is 7.34x versus 28.71x for FibroGen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of 1.42% compared to Harrow, Inc.'s net margin of -36.3%. Harrow, Inc.'s return on equity of -8.95% beat Myomo, Inc.'s return on equity of -68.35%.

Harrow, Inc. has a consensus price target of $70.63, signalling upside risk potential of 43.69%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 449.45%. Given that Myomo, Inc. has higher upside potential than Harrow, Inc., analysts believe Myomo, Inc. is more attractive than Harrow, Inc..

Harrow, Inc. has a beta of 0.068, which suggesting that the stock is 93.168% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

Harrow, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harrow, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Harrow, Inc. quarterly revenues are $71.6M, which are larger than Myomo, Inc. quarterly revenues of $10.1M. Harrow, Inc.'s net income of $1M is higher than Myomo, Inc.'s net income of -$3.7M. Notably, Harrow, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow, Inc. is 7.34x versus 0.90x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Skye Bioscience, Inc. has a net margin of 1.42% compared to Harrow, Inc.'s net margin of --. Harrow, Inc.'s return on equity of -8.95% beat Skye Bioscience, Inc.'s return on equity of -91.57%.

Harrow, Inc. has a consensus price target of $70.63, signalling upside risk potential of 43.69%. On the other hand Skye Bioscience, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 870.59%. Given that Skye Bioscience, Inc. has higher upside potential than Harrow, Inc., analysts believe Skye Bioscience, Inc. is more attractive than Harrow, Inc..

Harrow, Inc. has a beta of 0.068, which suggesting that the stock is 93.168% less volatile than S&P 500. In comparison Skye Bioscience, Inc. has a beta of 2.676, suggesting its more volatile than the S&P 500 by 167.642%.

Harrow, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Skye Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harrow, Inc. pays -- of its earnings as a dividend. Skye Bioscience, Inc. pays out -- of its earnings as a dividend.

Harrow, Inc. quarterly revenues are $71.6M, which are larger than Skye Bioscience, Inc. quarterly revenues of --. Harrow, Inc.'s net income of $1M is higher than Skye Bioscience, Inc.'s net income of -$12.8M. Notably, Harrow, Inc.'s price-to-earnings ratio is -- while Skye Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow, Inc. is 7.34x versus 476.49x for Skye Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theravance Biopharma, Inc. has a net margin of 1.42% compared to Harrow, Inc.'s net margin of 18.08%. Harrow, Inc.'s return on equity of -8.95% beat Theravance Biopharma, Inc.'s return on equity of 14.9%.

Harrow, Inc. has a consensus price target of $70.63, signalling upside risk potential of 43.69%. On the other hand Theravance Biopharma, Inc. has an analysts' consensus of $26.71 which suggests that it could grow by 43.86%. Given that Theravance Biopharma, Inc. has higher upside potential than Harrow, Inc., analysts believe Theravance Biopharma, Inc. is more attractive than Harrow, Inc..

Harrow, Inc. has a beta of 0.068, which suggesting that the stock is 93.168% less volatile than S&P 500. In comparison Theravance Biopharma, Inc. has a beta of 0.143, suggesting its less volatile than the S&P 500 by 85.696%.

Harrow, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theravance Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harrow, Inc. pays -- of its earnings as a dividend. Theravance Biopharma, Inc. pays out -- of its earnings as a dividend.

Harrow, Inc. quarterly revenues are $71.6M, which are larger than Theravance Biopharma, Inc. quarterly revenues of $20M. Harrow, Inc.'s net income of $1M is lower than Theravance Biopharma, Inc.'s net income of $3.6M. Notably, Harrow, Inc.'s price-to-earnings ratio is -- while Theravance Biopharma, Inc.'s PE ratio is 33.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harrow, Inc. is 7.34x versus 11.65x for Theravance Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.